Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Revenue of Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
Revenue in 2023 (TTM): $3.21 B
According to Jiangsu Hengrui Medicine Co., Ltd.'s latest financial reports the company's current revenue (TTM) is $3.21 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Jiangsu Hengrui Medicine Co., Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $3.21 B | $2.72 B | $777.82 M | $657.32 M | $605.96 M |
| 2022 | $3 B | $2.51 B | $668.53 M | $558.92 M | $550.17 M |
| 2021 | $3.65 B | $3.12 B | $715.59 M | $629.04 M | $638.04 M |
| 2020 | $3.91 B | $3.43 B | $1.04 B | $971.16 M | $891.29 M |
| 2019 | $3.28 B | $2.87 B | $939.02 M | $852.9 M | $750.4 M |
| 2018 | $2.45 B | $2.12 B | $691.03 M | $633.65 M | $572.6 M |
| 2017 | $1.95 B | $1.69 B | $574.14 M | $529.45 M | $453.03 M |
| 2016 | $1.56 B | $1.36 B | $459.66 M | $424.38 M | $364.63 M |
| 2015 | $1.31 B | $1.12 B | $394.06 M | $360.83 M | $305.84 M |
| 2014 | $1.05 B | $864.62 M | $284.54 M | $253.46 M | $213.45 M |
| 2013 | $873.64 M | $710.54 M | $233.2 M | $208.24 M | $174.38 M |
| 2012 | $765.48 M | $642.89 M | $201.85 M | $189.64 M | $151.74 M |
| 2011 | $640.88 M | $530.44 M | $173.89 M | $150 M | $123.46 M |
| 2010 | $527.32 M | $442.04 M | $133.92 M | $121.15 M | $101.99 M |
| 2009 | $426.6 M | $352.82 M | $91.22 M | $109.95 M | $93.76 M |
| 2008 | $336.97 M | $280.51 M | $129.68 M | $66.2 M | $59.57 M |
| 2007 | $276 M | $229.47 M | $52.57 M | $72.03 M | $58.16 M |
| 2006 | $200.34 M | $162.83 M | $49.42 M | $40.74 M | $29.1 M |
| 2005 | $166.09 M | $133.71 M | $39.48 M | $31.08 M | $22.85 M |
| 2004 | $161.28 M | $120.96 M | $32.51 M | $24.32 M | $17.27 M |
| 2003 | $147.93 M | $98.89 M | $29.18 M | $21.22 M | $13.31 M |
| 2002 | $106.48 M | $67.24 M | $20.5 M | $15.56 M | $11.12 M |
| 2001 | $89.33 M | $53.36 M | $17.99 M | $13.76 M | $11.43 M |
| 2000 | $68.27 M | $36.34 M | $14.69 M | $11.53 M | $9.19 M |
| 1999 | $58.3 M | $27.84 M | $11.61 M | $8.83 M | $7.23 M |
| 1998 | $51.24 M | $22.28 M | $8.18 M | $7.34 M | $6.09 M |
| 1997 | $42.75 M | $17.35 M | $5.92 M | $6.27 M | $5.78 M |